This HTML5 document contains 64 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n17https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
freebasehttp://rdf.freebase.com/ns/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbchttp://dbpedia.org/resource/Category:
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
goldhttp://purl.org/linguistics/gold/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Calvin_A._Grant
rdf:type
yago:WikicatAmericanOphthalmologists yago:WikicatAmericanPeopleOfJamaicanDescent yago:MedicalPractitioner110305802 yago:Object100002684 yago:Ophthalmologist110379073 yago:CausalAgent100007347 yago:Organism100004475 yago:Whole100003553 dbo:Person yago:PhysicalEntity100001930 yago:YagoLegalActor yago:YagoLegalActorGeo yago:Adult109605289 yago:Specialist110632576 yago:WikicatLivingPeople yago:LivingThing100004258 yago:Doctor110020890 yago:HealthProfessional110165109 yago:Person100007846 yago:Professional110480253
rdfs:label
Calvin A. Grant
rdfs:comment
Calvin Alexander Grant is an American ophthalmologist. Grant was born in 1970 in Washington, D.C., to Jamaican parents, and spent a large amount of his childhood in the Washington Metropolitan Area. At the age of 21 he attended the University of Pennsylvania School of Medicine where he received the for ophthalmological research. His earlier research in gene transfer to the retina using adeno-associated viruses was one of the first. This work was conducted under the Howard Hughes Medical Student Fellowship. Grant has also become the first to introduce in the treatment of choroidal melanoma.
dcterms:subject
dbc:Living_people dbc:American_people_of_Jamaican_descent dbc:1970_births dbc:Perelman_School_of_Medicine_at_the_University_of_Pennsylvania_alumni dbc:American_ophthalmologists
dbo:wikiPageID
17397598
dbo:wikiPageRevisionID
1068840370
dbo:wikiPageWikiLink
dbc:American_ophthalmologists dbr:Oliver_prize dbr:Washington,_D.C. dbr:Washington_Metropolitan_Area dbr:Choroidal_melanoma dbr:Bromfenac dbr:Retina dbr:Jamaica dbc:American_people_of_Jamaican_descent dbc:1970_births dbr:Robotic_radiosurgery dbr:Ischaemic dbr:University_of_Pennsylvania_School_of_Medicine dbr:Adeno dbr:Ophthalmologist dbc:Perelman_School_of_Medicine_at_the_University_of_Pennsylvania_alumni dbc:Living_people dbr:Central_retinal_vein_occlusion dbr:Viruses dbr:Gene_transfer
owl:sameAs
freebase:m.0463vj3 wikidata:Q5024312 yago-res:Calvin_A._Grant n17:4fTyy
dbp:wikiPageUsesTemplate
dbt:Reflist dbt:Unreliable_source%3F dbt:BLP_sources dbt:Multiple_issues dbt:BLP_self-published dbt:Citation_needed
dbo:abstract
Calvin Alexander Grant is an American ophthalmologist. Grant was born in 1970 in Washington, D.C., to Jamaican parents, and spent a large amount of his childhood in the Washington Metropolitan Area. At the age of 21 he attended the University of Pennsylvania School of Medicine where he received the for ophthalmological research. His earlier research in gene transfer to the retina using adeno-associated viruses was one of the first. This work was conducted under the Howard Hughes Medical Student Fellowship. Grant developed the first sustained treatment for ischaemic and non-ischaemic central retinal vein occlusion. His procedure, called revascularization by anastomotic decompression (RAD), allowed for communication between the blocked superficial retinal venous circulation and the open underlying choroidal circulation. In a press release issued by ISTA Pharmaceuticals, which has a strong interest in the success of the drug, it was claimed that Grant demonstrated a significant decrease in the number of treatments of ranibizumab (Lucentis) needed for the treatment of choroidal neovascularization secondary to age-related macular degeneration by the concomitant administration of bromfenac (Xibrom). There was a significant reduction in the number of injections of ranibizumab given to those patients also receiving bromfenac during a six-month period.ISTA Pharmaceuticals at first claimed that there was no statistically significant visual acuity improvement amongst those receiving bromfenac in addition to ranibizumab, however; they now claim that upon "rigorous review" a significant improvement can be detected. ISTA Pharmaceuticals states that these results will need to be verified in clinical studies and that bromfenac is not currently approved for the treatment of age-related macular degeneration. Grant has also become the first to introduce in the treatment of choroidal melanoma.
gold:hypernym
dbr:Grant
prov:wasDerivedFrom
wikipedia-en:Calvin_A._Grant?oldid=1068840370&ns=0
dbo:wikiPageLength
3284
foaf:isPrimaryTopicOf
wikipedia-en:Calvin_A._Grant